154 related articles for article (PubMed ID: 36644323)
21. Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies.
Heftdal LD; Hansen CB; Hamm SR; Pérez-Alós L; Fogh K; Pries-Heje M; Hasselbalch RB; Møller DL; Gang AO; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Garred P; Iversen K; Sabin C; Nielsen SD; Grønbæk K
Viruses; 2023 Dec; 16(1):. PubMed ID: 38275946
[TBL] [Abstract][Full Text] [Related]
22. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
Wang F; Huang B; Deng Y; Zhang S; Liu X; Wang L; Liu Q; Zhao L; Tang L; Wang W; Wang X; Ye F; Hu W; Yang H; Wang S; Ren J; Liu X; Wang C; Guan X; Wang R; Zheng Y; Zhang X; Zheng H; Wu D; An Z; Xu W; Rodewald LE; Gao GF; Yin Z; Tan W
BMC Med; 2023 Jul; 21(1):233. PubMed ID: 37400857
[TBL] [Abstract][Full Text] [Related]
23. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination.
Suntronwong N; Assawakosri S; Kanokudom S; Yorsaeng R; Auphimai C; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892491
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Katz Sand I; Gnjatic S; Krammer F; Tuballes K; Carreño JM; Satyanarayan S; Filomena S; Staker E; Tcheou J; Miller A; Fabian M; Safi N; Nichols J; Patel J; Krieger S; Tankou S; Horng S; Klineova S; Beck E; Merad M; Lublin F
Mult Scler Relat Disord; 2023 Feb; 70():104486. PubMed ID: 36628884
[TBL] [Abstract][Full Text] [Related]
25. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
[TBL] [Abstract][Full Text] [Related]
26. Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.
Diefenbach C; Caro J; Koide A; Grossbard M; Goldberg JD; Raphael B; Hymes K; Moskovits T; Kreditor M; Kaminetzky D; Fleur-Lominy SS; Choi J; Thannickal SA; Stapleford KA; Koide S
medRxiv; 2021 Jun; ():. PubMed ID: 34100025
[TBL] [Abstract][Full Text] [Related]
27. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.
Goh YS; Rouers A; Fong SW; Zhuo NZ; Hor PX; Loh CY; Huang Y; Neo VK; Kam IKJ; Wang B; Ngoh EZX; Salleh SNM; Lee RTC; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; ; ; Maurer-Stroh S; Wang CI; Leo YS; Ren EC; Lye DC; Young BE; Ng LFP; Renia L
Front Immunol; 2022; 13():1031852. PubMed ID: 36451833
[TBL] [Abstract][Full Text] [Related]
28. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
[TBL] [Abstract][Full Text] [Related]
29. High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.
Guirakhoo F; Wang S; Wang CY; Kuo HK; Peng WJ; Liu H; Wang L; Johnson M; Hunt A; Hu MM; Monath TP; Rumyantsev A; Goldblatt D
J Infect Dis; 2022 Oct; 226(8):1401-1406. PubMed ID: 35723969
[TBL] [Abstract][Full Text] [Related]
30. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
[TBL] [Abstract][Full Text] [Related]
31. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
[TBL] [Abstract][Full Text] [Related]
32. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
33. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
[TBL] [Abstract][Full Text] [Related]
34. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review.
Du Y; Chen L; Shi Y
Hum Vaccin Immunother; 2022 Nov; 18(5):2062983. PubMed ID: 35499517
[TBL] [Abstract][Full Text] [Related]
35. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.
Aleman A; van Kesteren M; Zajdman AK; Srivastava K; Cognigni C; Mischka J; Chen LY; Upadhyaya B; Serebryakova K; Nardulli JR; Lyttle N; Kappes K; Jackson H; Gleason CR; Oostenink A; Cai GY; Van Oekelen O; ; van Bakel H; Sordillo EM; Cordon-Cardo C; Merad M; Jagannath S; Wajnberg A; Simon V; Parekh S
EBioMedicine; 2023 Dec; 98():104886. PubMed ID: 37995467
[TBL] [Abstract][Full Text] [Related]
36. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
[TBL] [Abstract][Full Text] [Related]
37. Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: A longitudinal observational study.
Chen Z; Huang T; He T; Zha G; Zhu Q; Zhang G; Xiang D; Chen M; Li H; Ling N; Lan Y; Shi X; Zhang D; Xu P; Pan Q; Song R; Cao J; Zhang Y; Xiang H; Feng Y; Yang Z; Zhang B; Shen W; Cai D; Peng M; Hu P; Ren H
J Med Virol; 2023 Apr; 95(4):e28695. PubMed ID: 36946505
[TBL] [Abstract][Full Text] [Related]
38. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
[TBL] [Abstract][Full Text] [Related]
39. Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants.
Cheng HL; Lim SM; Jia H; Chen MW; Ng SY; Gao X; Somani J; Sengupta S; Tay DMY; Chua PWL; R A; Ling SYH; McBee ME; Young BE; Sikes HD; Preiser PR
Microbiol Spectr; 2022 Oct; 10(5):e0225722. PubMed ID: 36069616
[TBL] [Abstract][Full Text] [Related]
40. Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors.
Lu BN; Zhu KL; Cui XM; Yao L; Wang XJ; Wang GL; Duan LJ; Qian A; Ma MJ
Clin Immunol; 2022 Nov; 244():109103. PubMed ID: 36049602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
